BI 705564
Alternative Names: BI705564Latest Information Update: 12 Apr 2019
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 01 Apr 2019 Discontinued - Phase-I for Systemic lupus erythematosus (In volunteers) in Germany (PO)
- 01 Apr 2019 Boehringer Ingelheim withdraws a phase I trial in Japanese healthy volunteers prior to enrolment (NCT03747926)
- 07 Mar 2019 Boehringer Ingelheim withdraws the application for a phase I trial for Systemic lupus erythematosus in January 2019 prior to initiation due to strategic decision (NCT03771885)